Commission Implementing Regulation (EU) 2017/1126 of 23 June 2017 amending Regulation (EC) No 903/2009 and Implementing Regulations (EU) No 373/2011, (EU) No 374/2013 and (EU) No 1108/2014 as regards the name of the EU representative of the holder of the authorisation of a preparation of Clostridium butyricum (FERM-BP 2789) (Text with EEA relevance. )
Artículo 1Amendment to Regulation (EC) No 903/2009
Vigente · versión de 14 jul 2017
Regulation (EC) No 903/2009 is amended as follows:
(1) In the Title, the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd, represented by Miyarisan Pharmaceutical Europe S.L.U’ are replaced by the words ‘holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.
(2) In the Annex to Regulation (EC) No 903/2009, in the second column ‘Name of the holder of authorisation’, the words ‘Miyarisan Pharmaceutical Co. Ltd represented by Miyarisan Pharmaceutical Europe S.L.U.’ are replaced by the words ‘Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium’.